

1. Company

Galantos Pharma GmbH
Biotechnikum an der Goldgrube
Freiligrathstraße 12
D-55131 Mainz
Germany
Tel: +49 (6131) 1440 311
Fax: +49 (6131) 1440 329
URL: www.galantos.com
Contact: Dr. Andreas Köpke, CBO



2. Core Competences

Galantos Pharma GmbH is a biopharmaceutical company developing innovative drugs for the treatment of neurodegenerative diseases. At present, its focus is on the improvement of marketed drugs and natural substances for the treatment of Alzheimer's Disease (AD). Memogain, its most advanced product, is scheduled to move into clinical trials in 2009 and is expected to qualify for accelerated approval.

Long-standing expertise in Alzheimer's disease: founders and management of Galantos Pharma GmbH have a long-standing experience in the neuropathology of AD. Prof Maelicke's laboratory demonstrated, among others, that AD is accompanied by a severe loss of nicotinic acetylcholine receptors (nAChR) and later identified a novel class of nACh receptor ligands capable of enhancing the activity of remaining nAChRs, the so-called allosteric potentiating ligands (APLs).

Pipeline: the lead product of Galantos Pharma is Memogain, a derivative of the marketed drug galantamine, which is used for the treatment of AD since 2000. Memogain, a pro-drug, which is metabolized to galantamine in the brain, offers improved efficacy at reduced adverse events and clinical development in Alzheimer's disease (AD) is planned for 2009. It is expected that market approval of Memogain is fast (until 2010/11) and cost effective, as the pharmacologically active compound comes with long term clinical experience.

In addition, Galantos is exploring two novel neuroprotective compounds – an APL targeting nicotinic acetylcholine receptors in general (nAChRs) and a subtype-specific APL targeting the $\alpha 7$ nicotinic acetylcholine receptor. APLs enhance the sensitivity to ACh of nicotinic receptors and therefore overcome the well-established shortcomings of direct agonists: receptor desensitization and regulation of expression. Results in animal models indicate that enhancing the sensitivity of nAChRs has considerable therapeutic potential in AD and other CNS-related diseases.

3. Cooperations offered and requested

The Company aims to bring Memogain into clinical development by 2009 and to subsequently license the drug to a pharma partner.

Galantos Pharma further develops novel, causal and preventive therapies for AD and other neurological and psychiatric indications, based on allosteric modulation of nicotinic receptors and Galantos' existing leads. For these compounds, Galantos aims to form strategic alliances with big pharma partners to reduce development costs and the attrition rate of Alzheimer's medication candidates, creating a stable revenue stream.

Galantos Pharma has successful collaborations with a number of CROs and advisors world-wide and has currently no further partnering needs.